The US FDA’s first public unveiling of the planned overhaul of the Office of New Drugs is filling in some of the details on a critical structural change for biopharma companies.
One thing has been clear for several weeks: the new OND will have more drug review divisions and offices. (Also see "US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?" - Pink Sheet, 2 May, 2018